{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T17:34:09Z","timestamp":1766511249317,"version":"3.48.0"},"reference-count":239,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.cca.2025.120686","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:28:25Z","timestamp":1761550105000},"page":"120686","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Mesothelin in pancreatic cancer: clinical applications and analytical considerations"],"prefix":"10.1016","volume":"579","author":[{"given":"Neeraj","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riya","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soumya V.","family":"Menon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subhashree","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surya Nath","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavita","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haider","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandana","family":"Maji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rekha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaurav","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md Sadique","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2025.120686_bb0005","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4251\/wjgo.v12.i2.173","article-title":"Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment and immunotherapy","volume":"12","author":"Sarantis","year":"2020","journal-title":"World J. Gastrointestinal Oncol."},{"key":"10.1016\/j.cca.2025.120686_bb0010","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/carcin\/bgp263","article-title":"The global burden of cancer: priorities for prevention","volume":"31","author":"Thun","year":"2010","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.cca.2025.120686_bb0015","first-page":"15","article-title":"State-of-the-art and upcoming innovations in pancreatic Cancer care: a step forward to precision medicine","author":"Schepis","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.cca.2025.120686_bb0020","first-page":"6","article-title":"MXene-montmorillonite nanocomposites-based scaffold sensors for early pancreatic cancer diagnosis","author":"Sadiq","year":"2024","journal-title":"Cancer Plus"},{"key":"10.1016\/j.cca.2025.120686_bb0025","first-page":"13","article-title":"Non-invasive biomarkers for earlier detection of pancreatic cancer-a comprehensive review","author":"Brezgyte","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.cca.2025.120686_bb0030","first-page":"1","article-title":"Clinical features, treatment, and prognosis of SGLT2 inhibitors induced acute pancreatitis","author":"Li","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.cca.2025.120686_bb0035","first-page":"13","article-title":"Biomarkers as prognostic predictors and therapeutic guide in critically ill patients: clinical evidence","author":"M\u00e9ndez Hern\u00e1ndez","year":"2023","journal-title":"J. Personalized Med."},{"key":"10.1016\/j.cca.2025.120686_bb0040","doi-asserted-by":"crossref","first-page":"340","DOI":"10.14740\/wjon1655","article-title":"Biology of Mesothelin and clinical implications: a review of existing literature","volume":"14","author":"Hagerty","year":"2023","journal-title":"World. J. Oncol."},{"key":"10.1016\/j.cca.2025.120686_bb0045","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1158\/2767-9764.CRC-22-0306","article-title":"Structures of Cancer antigen Mesothelin and its complexes with therapeutic antibodies","volume":"3","author":"Zhan","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.cca.2025.120686_bb0050","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3389\/fonc.2020.01263","article-title":"Insights into the role of Mesothelin as a diagnostic and therapeutic target in ovarian carcinoma","volume":"10","author":"Shen","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cca.2025.120686_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexmp.2014.09.016","article-title":"Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targets","volume":"97","author":"Ram\u00edrez-Salazar","year":"2014","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.cca.2025.120686_bb0060","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/s41417-024-00816-1","article-title":"Mesothelin expression correlates with elevated inhibitory immune activity in patients with colorectal cancer","volume":"31","author":"Malla","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.cca.2025.120686_bb0065","first-page":"105","article-title":"The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal","volume":"3","author":"Ballehaninna","year":"2012","journal-title":"J. Gastrointestinal Oncol."},{"key":"10.1016\/j.cca.2025.120686_bb0070","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1186\/s12885-025-13929-z","article-title":"Development of PDAC diagnosis and prognosis evaluation models based on machine learning","volume":"25","author":"Xiao","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cca.2025.120686_bb0075","doi-asserted-by":"crossref","DOI":"10.1021\/acsabm.5c00738","article-title":"Plasmonic ELISA for biomarker detection: a review of mechanisms, functionalization strategies, and emerging modalities","author":"Shoukat","year":"2025","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.cca.2025.120686_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101747","article-title":"Diagnostic accuracy and added value of blood-based protein biomarkers for pancreatic cancer: a meta-analysis of aggregate and individual participant data","volume":"55","author":"Boyd","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.cca.2025.120686_bb0085","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1177\/147323001204000309","article-title":"Clinicopathological significance of mesothelin expression in invasive breast cancer","volume":"40","author":"Wang","year":"2012","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.cca.2025.120686_bb0090","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12943-020-01151-3","article-title":"Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma","volume":"19","author":"Fan","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.cca.2025.120686_bb0095","first-page":"17","article-title":"Mesothelin-associated anti-senescence through P53 in pancreatic ductal adenocarcinoma","author":"Liu","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.cca.2025.120686_bb0100","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.3390\/cancers16122240","article-title":"Pancreatic ductal adenocarcinoma (PDAC): a review of recent advancements enabled by artificial intelligence","volume":"16","author":"Mukund","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.cca.2025.120686_bb0105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.25259\/Cytojournal_105_2024","article-title":"Methyltransferase-like 14 promotes the tumorigenesis and proliferation of pancreatic cancer cells through myc proto-oncogene signaling pathway","volume":"21","author":"Li","year":"2024","journal-title":"CytoJournal"},{"key":"10.1016\/j.cca.2025.120686_bb0110","first-page":"14","article-title":"Pancreatic cancer: challenges and opportunities in locoregional therapies","author":"Bazeed","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.cca.2025.120686_bb0115","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3892\/ol.2025.15116","article-title":"Diagnostic methods for pancreatic cancer and their clinical applications (review)","volume":"30","author":"Zhao","year":"2025","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.cca.2025.120686_bb0120","first-page":"127","article-title":"Artificial intelligence in cancer imaging: clinical challenges and applications","volume":"69","author":"Bi","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.cca.2025.120686_bb0125","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.clinimag.2015.06.003","article-title":"Imaging-based screening: maximizing benefits and minimizing harms","volume":"40","author":"Germino","year":"2016","journal-title":"Clin. Imaging"},{"key":"10.1016\/j.cca.2025.120686_bb0130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4103\/2303-9027.117691","article-title":"Endoscopic ultrasound-guided fine needle aspiration: from the past to the future","volume":"2","author":"Costache","year":"2013","journal-title":"Endoscopic Ultrasound"},{"key":"10.1016\/j.cca.2025.120686_bb0135","doi-asserted-by":"crossref","first-page":"468","DOI":"10.4240\/wjgs.v12.i12.468","article-title":"Carbohydrate antigen 19-9 - tumor marker: past, present, and future","volume":"12","author":"Lee","year":"2020","journal-title":"World J. Gastrointestinal Surgery"},{"key":"10.1016\/j.cca.2025.120686_bb0140","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1109\/TCBB.2020.2973148","article-title":"FUNMarker: fusion network-based method to identify prognostic and heterogeneous breast Cancer biomarkers","volume":"18","author":"Li","year":"2021","journal-title":"IEEE\/ACM Trans. Comput. Biol. Bioinform."},{"key":"10.1016\/j.cca.2025.120686_bb0145","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41392-024-01823-2","article-title":"Tumor biomarkers for diagnosis, prognosis and targeted therapy","volume":"9","author":"Zhou","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cca.2025.120686_bb0150","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1208\/s12248-010-9182-4","article-title":"Successes achieved and challenges ahead in translating biomarkers into clinical applications","volume":"12","author":"Tesch","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.cca.2025.120686_bb0155","first-page":"25","article-title":"The circulating biomarkers league: combining miRNAs with cell-free DNAs and proteins","author":"Felekkis","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cca.2025.120686_bb0160","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.2147\/OTT.S142149","article-title":"Biomarkers for early diagnosis, prognosis, prediction, and recurrence monitoring of non-small cell lung cancer","volume":"10","author":"Tang","year":"2017","journal-title":"Onco. Targets. Ther."},{"key":"10.1016\/j.cca.2025.120686_bb0165","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3390\/biom10070973","article-title":"Mesothelin-targeted recombinant immunotoxins for solid tumors","volume":"10","author":"Hagerty","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.cca.2025.120686_bb0170","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13062-024-00518-6","article-title":"Disulfidptosis signature predicts immune microenvironment and prognosis of gastric cancer","volume":"19","author":"Liu","year":"2024","journal-title":"Biol. Direct"},{"key":"10.1016\/j.cca.2025.120686_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19336918.2024.2395807","article-title":"Liquid biopsy: paving a new avenue for cancer research","volume":"18","author":"Kurma","year":"2024","journal-title":"Cell Adhes. Migr."},{"key":"10.1016\/j.cca.2025.120686_bb0180","article-title":"Liquid biopsy: an evolving paradigm for non-invasive disease diagnosis and monitoring in medicine","volume":"15","author":"Adhit","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.cca.2025.120686_bb0185","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3390\/bios13030387","article-title":"Biomarker detection in early diagnosis of cancer: recent achievements in point-of-care devices based on paper microfluidics","volume":"13","author":"Asci Erkocyigit","year":"2023","journal-title":"Biosensors"},{"key":"10.1016\/j.cca.2025.120686_bb0190","doi-asserted-by":"crossref","first-page":"16902","DOI":"10.1038\/s41598-025-99351-8","article-title":"Electrochemical surface plasmon resonance based biosensor for \u03b1-fetoprotein detection via different coupling strategies","volume":"15","author":"Thakur","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cca.2025.120686_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2024.130706","article-title":"COPZ1 regulates ferroptosis through NCOA4-mediated ferritinophagy in lung adenocarcinoma","volume":"1868","author":"Wu","year":"2024","journal-title":"Biochim. Biophys. Acta, Gen. Subj."},{"key":"10.1016\/j.cca.2025.120686_bb0200","first-page":"1","article-title":"A Femtomolar detection range via Plasmonic biosensors based on V-shaped optical adhesives waveguides","author":"Prete","year":"2023","journal-title":"IEEE Sensors J."},{"key":"10.1016\/j.cca.2025.120686_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100705","article-title":"Future of artificial intelligence\u2014machine learning trends in pathology and medicine","volume":"38","author":"Hanna","year":"2025","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.cca.2025.120686_bb0210","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1111\/febs.16768","article-title":"MAEL facilitates metabolic reprogramming and breast cancer progression by promoting the degradation of citrate synthase and fumarate hydratase via chaperone-mediated autophagy","volume":"290","author":"Zhou","year":"2023","journal-title":"FEBS J."},{"key":"10.1016\/j.cca.2025.120686_bb0215","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s13195-023-01304-8","article-title":"Systematic review: fluid biomarkers and machine learning methods to improve the diagnosis from mild cognitive impairment to Alzheimer\u2019s disease","volume":"15","author":"Blanco","year":"2023","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"10.1016\/j.cca.2025.120686_bb0220","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/MPA.0000000000001762","article-title":"Artificial intelligence and early detection of pancreatic cancer: 2020 summative review","volume":"50","author":"Kenner","year":"2021","journal-title":"Pancreas"},{"key":"10.1016\/j.cca.2025.120686_bb0225","doi-asserted-by":"crossref","first-page":"8678","DOI":"10.3748\/wjg.v21.i28.8678","article-title":"Screening for pancreatic cancer in familial high-risk individuals: a systematic review","volume":"21","author":"Lu","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.cca.2025.120686_bb0230","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gendis.2018.05.001","article-title":"Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis","volume":"5","author":"Feng","year":"2018","journal-title":"Genes & Diseases"},{"key":"10.1016\/j.cca.2025.120686_bb0235","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1080\/21691401.2023.2274047","article-title":"Advances in screening and diagnostic lab-on-chip tools for gynaecological cancers \u2013 a review","volume":"51","author":"Nujhat","year":"2023","journal-title":"Artificial Cells, Nanomedicine Biotechnol."},{"issue":"Suppl. 3","key":"10.1016\/j.cca.2025.120686_bb0240","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1093\/cid\/cit578","article-title":"Better tests, better care: improved diagnostics for infectious diseases","volume":"57","author":"Caliendo","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.cca.2025.120686_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.envint.2025.109601","article-title":"Guidance on minimum information requirements (MIR) from designing to reporting human biomonitoring (HBM)","author":"Zare Jeddi","year":"2025","journal-title":"Environ. Int."},{"key":"10.1016\/j.cca.2025.120686_bb0250","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1101\/gad.275776.115","article-title":"Genetics and biology of pancreatic ductal adenocarcinoma","volume":"30","author":"Ying","year":"2016","journal-title":"Genes Dev."},{"key":"10.1016\/j.cca.2025.120686_bb0255","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.3390\/s25061936","article-title":"Microfluidic biosensors: enabling advanced disease detection","volume":"25","author":"Wang","year":"2025","journal-title":"Sensors"},{"key":"10.1016\/j.cca.2025.120686_bb0260","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1053\/j.gastro.2019.01.259","article-title":"Early detection of pancreatic Cancer: opportunities and challenges","volume":"156","author":"Singhi","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cca.2025.120686_bb0265","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13578-024-01213-9","article-title":"Deubiquitinase PSMD7 facilitates pancreatic cancer progression through activating Nocth1 pathway via modifying SOX2 degradation","volume":"14","author":"Luo","year":"2024","journal-title":"Cell Biosci."},{"key":"10.1016\/j.cca.2025.120686_bb0270","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/17501911.2025.2535938","article-title":"Epigenetic alterations in prostate cancer: the role of chromatin remodeling","volume":"17","author":"Hussain","year":"2025","journal-title":"Epigenomics"},{"key":"10.1016\/j.cca.2025.120686_bb0275","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s42003-020-01464-5","article-title":"Multiple proteases are involved in mesothelin shedding by cancer cells","volume":"3","author":"Liu","year":"2020","journal-title":"Communications Biology"},{"key":"10.1016\/j.cca.2025.120686_bb0280","first-page":"14","article-title":"Mesothelin: an immunotherapeutic target beyond solid tumors","author":"Faust","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.cca.2025.120686_bb0285","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.bbrc.2017.01.044","article-title":"Signal peptidase I processed secretory signal sequences: selection for and against specific amino acids at the second position of mature protein","volume":"483","author":"Zalucki","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cca.2025.120686_bb0290","doi-asserted-by":"crossref","first-page":"16399","DOI":"10.1074\/jbc.M112.350009","article-title":"Efficient glycosylphosphatidylinositol (GPI) modification of membrane proteins requires a C-terminal anchoring signal of marginal hydrophobicity","volume":"287","author":"Galian","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2025.120686_bb0295","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1128\/JVI.77.5.2981-2989.2003","article-title":"Furin processing and proteolytic activation of Semliki Forest virus","volume":"77","author":"Zhang","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.cca.2025.120686_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009246","article-title":"Furin cleavage of SARS-CoV-2 spike promotes but is not essential for infection and cell-cell fusion","volume":"17","author":"Papa","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.cca.2025.120686_bb0305","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3390\/cancers14061550","article-title":"Mesothelin: an immunotherapeutic target beyond solid tumors","volume":"14","author":"Faust","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.cca.2025.120686_bb0310","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.3390\/diagnostics11112015","article-title":"Pilot study to evaluate serum soluble Mesothelin-related peptide (SMRP) as marker for clinical monitoring of pleural mesothelioma (PM): correlation with modified RECIST score","volume":"11","author":"Grosso","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.cca.2025.120686_bb0315","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202400446R","article-title":"Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization","volume":"38","author":"Ewa","year":"2024","journal-title":"FASEB J."},{"key":"10.1016\/j.cca.2025.120686_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6807-9-1","article-title":"Mesothelin, stereocilin, and otoancorin are predicted to have superhelical structures with ARM-type repeats","volume":"9","author":"Sathyanarayana","year":"2009","journal-title":"BMC Struct. Biol."},{"key":"10.1016\/j.cca.2025.120686_bb0325","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4071508","article-title":"Predictions of apoptosis proteins by integrating different features based on improving Pseudo-position-specific scoring matrix","volume":"2020","author":"Ruan","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.cca.2025.120686_bb0330","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1021\/acs.jpcb.1c00771","article-title":"The N-terminal Helix-turn-Helix motif of transcription factors MarA and rob drives DNA recognition","volume":"125","author":"Corbella","year":"2021","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.cca.2025.120686_bb0335","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.3390\/toxins2112519","article-title":"Toxin-based therapeutic approaches","volume":"2","author":"Shapira","year":"2010","journal-title":"Toxins"},{"key":"10.1016\/j.cca.2025.120686_bb0340","doi-asserted-by":"crossref","DOI":"10.4161\/idp.24684","article-title":"The alphabet of intrinsic disorder: II. Various roles of glutamic acid in ordered and intrinsically disordered proteins","volume":"1","author":"Uversky","year":"2013","journal-title":"Intrinsically Disordered Proteins"},{"key":"10.1016\/j.cca.2025.120686_bb0345","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1158\/1541-7786.MCR-08-0095","article-title":"Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3","volume":"6","author":"Bharadwaj","year":"2008","journal-title":"Mol. Cancer Res.: MCR."},{"key":"10.1016\/j.cca.2025.120686_bb0350","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41392-024-01759-7","article-title":"Protein lipidation in health and disease: molecular basis, physiological function and pathological implication","volume":"9","author":"Yuan","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cca.2025.120686_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112730","article-title":"Cancer-associated mesothelial cells are regulated by the anti-M\u00fcllerian hormone axis","volume":"42","author":"Chauvin","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.cca.2025.120686_bb0360","first-page":"22","article-title":"Host Mesothelin expression increases ovarian Cancer metastasis in the peritoneal microenvironment","author":"Hilliard","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cca.2025.120686_bb0365","article-title":"Megakaryocytic potentiating factor and mature mesothelin stimulate the growth of a lung cancer cell line in the peritoneal cavity of mice","volume":"9","author":"Zhang","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.cca.2025.120686_bb0370","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12943-017-0633-8","article-title":"Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells","volume":"16","author":"He","year":"2017","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.cca.2025.120686_bb0375","first-page":"17","article-title":"Mesothelin as a signal pathways and epigenetic target in Cancer therapy","author":"Kumari","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.cca.2025.120686_bb0380","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-024-01561-6","article-title":"Current and future immunotherapeutic approaches in pancreatic cancer treatment","volume":"17","author":"Farhangnia","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cca.2025.120686_bb0385","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.21037\/tcr-24-1832","article-title":"High-frequency KRAS mutations in pancreatic adenocarcinoma: prognostic significance and potential co-targeting therapies","volume":"14","author":"Yu","year":"2025","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.cca.2025.120686_bb0390","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29771","article-title":"Activation of the mitogen-activated protein kinase-extracellular signal-regulated kinase pathway in childhood B-cell acute lymphoblastic leukemia","volume":"69","author":"Pillai","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.cca.2025.120686_bb0395","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1158\/1535-7163.MCT-23-0519","article-title":"KRAS-driven tumorigenesis and KRAS-driven therapy in pancreatic adenocarcinoma","volume":"23","author":"Than","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.cca.2025.120686_bb0400","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1042\/BCJ20220550","article-title":"Characterizing crosstalk in epigenetic signaling to understand disease physiology","volume":"480","author":"Lempi\u00e4inen","year":"2023","journal-title":"Biochem. J."},{"key":"10.1016\/j.cca.2025.120686_bb0405","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/386561","article-title":"Aberrant MicroRNAs in pancreatic Cancer: researches and clinical implications","volume":"2014","author":"Sun","year":"2014","journal-title":"Gastroenterol. Res. Pract."},{"key":"10.1016\/j.cca.2025.120686_bb0410","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.semcancer.2022.03.021","article-title":"Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment","volume":"86","author":"Bhatia","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.cca.2025.120686_bb0415","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1749-6632.2009.04911.x","article-title":"Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?","volume":"1171","author":"Aggarwal","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.cca.2025.120686_bb0420","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3389\/fmolb.2019.00160","article-title":"Extracellular matrix in the tumor microenvironment and its impact on Cancer therapy","volume":"6","author":"Henke","year":"2019","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.cca.2025.120686_bb0425","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13045-020-01030-w","article-title":"Targeting hypoxic tumor microenvironment in pancreatic cancer","volume":"14","author":"Tao","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cca.2025.120686_bb0430","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s12935-024-03518-8","article-title":"The axis of tumor-associated macrophages, extracellular matrix proteins, and cancer-associated fibroblasts in oncogenesis","volume":"24","author":"Yu","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.cca.2025.120686_bb0435","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12935-020-01370-0","article-title":"Implications of HIF-1\u03b1 in the tumorigenesis and progression of pancreatic cancer","volume":"20","author":"Jin","year":"2020","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.cca.2025.120686_bb0440","series-title":"Encyclopedia of Cancer","first-page":"2836","article-title":"Micronucleus Assay","author":"Djuzenova","year":"2017"},{"key":"10.1016\/j.cca.2025.120686_bb0445","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41392-024-01885-2","article-title":"Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cca.2025.120686_bb0450","first-page":"219","article-title":"MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering \u03b2-catenin signaling","volume":"5","author":"Giannakouros","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.cca.2025.120686_bb0455","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13014-019-1345-6","article-title":"Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches","volume":"14","author":"Orth","year":"2019","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.cca.2025.120686_bb0460","first-page":"14","article-title":"Gene therapy using nanocarriers for pancreatic ductal adenocarcinoma: applications and challenges in cancer therapeutics","author":"Won","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.cca.2025.120686_bb0465","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/1878-0261.12096","article-title":"Revisiting epithelial-mesenchymal transition in cancer metastasis: the connection between epithelial plasticity and stemness","volume":"11","author":"Liao","year":"2017","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.cca.2025.120686_bb0470","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/14712598.2021.1843628","article-title":"Mesothelin-targeted CAR-T cell therapy for solid tumors","volume":"21","author":"Klampatsa","year":"2021","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.cca.2025.120686_bb0475","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cca.2025.120686_bb0480","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1155\/2013\/874212","article-title":"Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum","volume":"35","author":"Creaney","year":"2013","journal-title":"Dis. Markers"},{"key":"10.1016\/j.cca.2025.120686_bb0485","first-page":"14","article-title":"Development of a multiprotein classifier for the detection of early stage ovarian Cancer","author":"Boylan","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.cca.2025.120686_bb0490","first-page":"28","article-title":"MUC16: Molecular analysis and its functional implications in benign and malignant conditions","author":"Haridas","year":"2014","journal-title":"FASEB J.: Official Publication of the Federation of American Societies forExp. Biol."},{"key":"10.1016\/j.cca.2025.120686_bb0495","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1245\/s10434-025-17117-y","article-title":"Mesothelin (MSLN) is highly expressed in triple negative breast cancer and is associated with enhanced cell proliferation and Proinflammatory tumor microenvironment","volume":"32","author":"Hagerty","year":"2025","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.cca.2025.120686_bb0500","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3390\/cancers15051357","article-title":"Challenges of anti-mesothelin CAR-T-cell therapy","volume":"15","author":"Zhai","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.cca.2025.120686_bb0505","article-title":"MSLN induced EMT, cancer stem cell traits and chemotherapy resistance of pancreatic cancer cells","volume":"10","author":"Hu","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.cca.2025.120686_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocon.2023.110170","article-title":"Identifying functionally distinctive and threatened species","volume":"284","author":"Pavoine","year":"2023","journal-title":"Biol. Conserv."},{"key":"10.1016\/j.cca.2025.120686_bb0515","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.fmre.2022.01.037","article-title":"Integration of artificial intelligence and multi-omics in kidney diseases","volume":"3","author":"Zhou","year":"2023","journal-title":"Fundamental Res."},{"key":"10.1016\/j.cca.2025.120686_bb0520","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1007\/s12325-020-01520-w","article-title":"Mesothelin expression in patients with high-grade serous ovarian Cancer does not predict clinical outcome but correlates with CD11c(+) expression in tumor","volume":"37","author":"Magalhaes","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.cca.2025.120686_bb0525","doi-asserted-by":"crossref","DOI":"10.3390\/bios13100926","article-title":"Current status and emerging trends in colorectal Cancer screening and diagnostics","volume":"13","author":"Beniwal","year":"2023","journal-title":"Biosensors"},{"key":"10.1016\/j.cca.2025.120686_bb0530","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.4161\/epi.6.8.16074","article-title":"The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma","volume":"6","author":"Nelson","year":"2011","journal-title":"Epigenetics"},{"key":"10.1016\/j.cca.2025.120686_bb0535","series-title":"Impact of Point-of-Care Testing on Diagnosis, Treatment, and Surveillance of Vaccine-Preventable Viral Infections","first-page":"15","author":"Lakshmanan","year":"2025"},{"key":"10.1016\/j.cca.2025.120686_bb0540","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/joim.13709","article-title":"Precision cancer medicine: concepts, current practice, and future developments","volume":"294","author":"Edsj\u00f6","year":"2023","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.cca.2025.120686_bb0545","first-page":"4000","article-title":"Diagnostic value of mesothelinin pancreatic cancer: a meta-analysis","volume":"7","author":"Zhu","year":"2014","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.cca.2025.120686_bb0550","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/hpb.12199","article-title":"Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer","volume":"16","author":"Kendrick","year":"2014","journal-title":"HPB\u202f: Official J. Int. Hepato Pancreato Biliary Association"},{"key":"10.1016\/j.cca.2025.120686_bb0555","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2004.07.039","article-title":"Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma","volume":"95","author":"McIntosh","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.cca.2025.120686_bb0560","article-title":"Biosensors as diagnostic tools in clinical applications. Biochimica et Biophysica Acta (BBA) - reviews on","volume":"1877","author":"Lino","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.cca.2025.120686_bb0565","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.1112327","article-title":"Recent progress of microfluidic chips in immunoassay","volume":"10","author":"Wu","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.cca.2025.120686_bb0570","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/infa.12186","article-title":"Sample size, statistical power, and false conclusions in infant looking-time research","volume":"22","author":"Oakes","year":"2017","journal-title":"Infancy\u202f: Official J. Int. Soc. Infant Studies"},{"key":"10.1016\/j.cca.2025.120686_bb0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2023.105613","article-title":"Molecular point-of-care devices for the diagnosis of infectious diseases in resource-limited settings \u2013 a review of the current landscape, technical challenges, and clinical impact","volume":"169","author":"Gavina","year":"2023","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.cca.2025.120686_bb0580","first-page":"13","article-title":"Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engager","author":"Kosti","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.cca.2025.120686_bb0585","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/acs.jproteome.4c00752","article-title":"Biomarker discovery for early detection of pancreatic ductal adenocarcinoma (PDAC) using multiplex proteomics technology","volume":"24","author":"Athanasiou","year":"2025","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.cca.2025.120686_bb0590","first-page":"23","article-title":"Lectin-based assay for glycoform-specific detection of \u03b12,6-sialylated transferrin and carcinoembryonic antigen in tissue and body fluid","author":"Ito","year":"2018","journal-title":"Molecules (Basel, Switzerland)"},{"key":"10.1016\/j.cca.2025.120686_bb0595","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/bios7010007","article-title":"Surface-enhanced Raman scattering-based immunoassay technologies for detection of disease biomarkers","author":"Smolsky","year":"2017","journal-title":"Biosensors (Basel)"},{"key":"10.1016\/j.cca.2025.120686_bb0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.sbsr.2025.100826","article-title":"Advances in cancer detection: a review on electrochemical biosensor technologies","volume":"49","author":"Saasa","year":"2025","journal-title":"Sensing and Bio-Sensing Res."},{"key":"10.1016\/j.cca.2025.120686_bb0605","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1586\/14737159.2014.888313","article-title":"Advances and challenges in biosensor-based diagnosis of infectious diseases","volume":"14","author":"Sin","year":"2014","journal-title":"Expert Rev. Mol. Diagn."},{"key":"10.1016\/j.cca.2025.120686_bb0610","first-page":"11","article-title":"Ferreira HA. Nucleic acid aptamer-based biosensors: a review","author":"Sequeira-Antunes","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.cca.2025.120686_bb0615","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1021\/ac103161b","article-title":"Simultaneous detection of single molecules and Singulated ensembles of molecules enables immunoassays with broad dynamic range","volume":"83","author":"Rissin","year":"2011","journal-title":"Anal. Chem."},{"key":"10.1016\/j.cca.2025.120686_bb0620","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/carcin\/bgr075","article-title":"Mesothelin overexpression promotes autocrine IL-6\/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation","volume":"32","author":"Bharadwaj","year":"2011","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.cca.2025.120686_bb0625","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1021\/cb500904b","article-title":"Mass spectrometry-based detection and assignment of protein posttranslational modifications","volume":"10","author":"Doll","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.cca.2025.120686_bb0630","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.fmre.2024.04.021","article-title":"Role of artificial intelligence in revolutionizing drug discovery","volume":"5","author":"Rehman","year":"2025","journal-title":"Fundamental Res."},{"key":"10.1016\/j.cca.2025.120686_bb0635","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.4905","article-title":"An optimised indirect ELISA protocol for detection and quantification of anti-viral antibodies in human plasma or serum: a case study using SARS-CoV-2","volume":"13","author":"Baine","year":"2023","journal-title":"Bio-protocol"},{"key":"10.1016\/j.cca.2025.120686_bb0640","first-page":"423","article-title":"The diagnosis and treatment of systemic lupus erythematosus","volume":"112","author":"Kuhn","year":"2015","journal-title":"Deutsches Arzteblatt Int."},{"key":"10.1016\/j.cca.2025.120686_bb0645","doi-asserted-by":"crossref","first-page":"80208","DOI":"10.18632\/oncotarget.20303","article-title":"Mesothelin as a novel biomarker and immunotherapeutic target in human glioblastoma","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cca.2025.120686_bb0650","article-title":"Paper-based ELISA for fast CA 15\u20133 detection in point-of-care","volume":"181","author":"M","year":"2022","journal-title":"Microchem. J."},{"key":"10.1016\/j.cca.2025.120686_bb0655","doi-asserted-by":"crossref","DOI":"10.1177\/03000605251315913","article-title":"An overview of ELISA: a review and update on best laboratory practices for quantifying peptides and proteins in biological fluids","volume":"53","author":"Aydin","year":"2025","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.cca.2025.120686_bb0660","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1590\/0100-3984.2014.0119","article-title":"Receiver operating characteristic (ROC) curve for classification of (18)F-NaF uptake on PET\/CT","volume":"49","author":"Valadares","year":"2016","journal-title":"Radiol. Bras."},{"key":"10.1016\/j.cca.2025.120686_bb0665","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.mex.2017.03.002","article-title":"An ELISA protocol to improve the accuracy and reliability of serological antibody assays","volume":"4","author":"Waritani","year":"2017","journal-title":"MethodsX"},{"key":"10.1016\/j.cca.2025.120686_bb0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2025.113847","article-title":"ELISA protein detector (EPD): a Python-based ELISA tool for accurate low-level protein quantification","volume":"539","author":"Lu","year":"2025","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.cca.2025.120686_bb0675","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2147\/IJN.S435787","article-title":"Specific targeting of Mesothelin-expressing malignant cells using Nanobody-functionalized magneto-fluorescent Nanoassemblies","volume":"19","author":"Briolay","year":"2024","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.cca.2025.120686_bb0680","doi-asserted-by":"crossref","first-page":"13537","DOI":"10.3390\/ijms222413537","article-title":"On the road to accurate protein biomarkers in prostate Cancer diagnosis and prognosis: current status and future advances","volume":"22","author":"Yan","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cca.2025.120686_bb0685","first-page":"12","article-title":"Revolutionizing personalized medicine: synergy with multi-omics data generation, main hurdles, and future perspectives","author":"Molla","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.cca.2025.120686_bb0690","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1158\/1078-0432.CCR-09-0565","article-title":"Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer","volume":"15","author":"Johnston","year":"2009","journal-title":"Clinical Cancer Res.: An Official J. American Association for Cancer Res."},{"key":"10.1016\/j.cca.2025.120686_bb0695","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1535370217750088","article-title":"Biomarker definitions and their applications","volume":"243","author":"Califf","year":"2018","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.cca.2025.120686_bb0700","first-page":"1375","article-title":"Secretion of N-ERC\/mesothelin and expression of C-ERC\/mesothelin in human pancreatic ductal carcinoma","volume":"20","author":"Inami","year":"2008","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.cca.2025.120686_bb0705","article-title":"Expansion of anti-mesothelin specific CD4+ and CD8+ T cell responses in patients with pancreatic carcinoma","volume":"9","author":"Chen","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.cca.2025.120686_bb0710","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00216-016-9880-6","article-title":"Glycans and glycoproteins as specific biomarkers for cancer","volume":"409","author":"Kailemia","year":"2017","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.cca.2025.120686_bb0715","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41392-024-01886-1","article-title":"Glycosylation: mechanisms, biological functions and clinical implications","volume":"9","author":"He","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cca.2025.120686_bb0720","first-page":"10","article-title":"Characterization of Mesothelin glycosylation in pancreatic Cancer: decreased Core Fucosylated Glycoforms in pancreatic Cancer patients\u2019 sera","author":"Duran","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.cca.2025.120686_bb0725","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s13311-023-01410-3","article-title":"The role of clinical assessment in the era of biomarkers","volume":"20","author":"Carlos","year":"2023","journal-title":"Neurotherapeutics\u202f: J. American Society for Experimental NeuroTherapeutics"},{"key":"10.1016\/j.cca.2025.120686_bb0730","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1476-4598-13-129","article-title":"MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress","volume":"13","author":"Felder","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.cca.2025.120686_bb0735","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/ijc.34111","article-title":"Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer","volume":"151","author":"Jain","year":"2022","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.cca.2025.120686_bb0740","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1268927","article-title":"Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with malignant pleural mesothelioma","volume":"14","author":"Qualiotto","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2025.120686_bb1180","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.4269\/ajtmh.17-0879","article-title":"Biomarkers for the diagnosis of cholangiocarcinoma: a systematic review","volume":"98","author":"Tshering","year":"2018","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.cca.2025.120686_bb1170","article-title":"Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4","volume":"16","author":"Ghose","year":"2024","journal-title":"Therapeutic Adv. Med. Ooncol."},{"key":"10.1016\/j.cca.2025.120686_bb1175","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1074\/jbc.M806776200","article-title":"A binding domain on mesothelin for CA125\/MUC16","volume":"284","author":"Kaneko","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2025.120686_bb1185","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.3892\/or.2017.5471","article-title":"Novel quantitative analysis of the S100P protein combined with endoscopic ultrasound-guided fine needle aspiration cytology in the diagnosis of pancreatic adenocarcinoma","volume":"37","author":"Chiba","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.cca.2025.120686_bb0760","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1472-6890-14-35","article-title":"Expression of KOC, S100P, mesothelin and MUC1 in pancreatico-biliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panel","volume":"14","author":"Ali","year":"2014","journal-title":"BMC Clin. Pathol."},{"key":"10.1016\/j.cca.2025.120686_bb1190","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.799025","article-title":"Review of immunohistochemistry biomarkers in pancreatic Cancer diagnosis","volume":"11","author":"Luu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cca.2025.120686_bb0745","article-title":"Exploring tumor-promoting qualities of Cancer-associated fibroblasts and innovative drug discovery strategies with emphasis on Thymoquinone","volume":"16","author":"Padathpeedika Khalid","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.cca.2025.120686_bb0750","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s40364-021-00335-3","article-title":"Co-expression of mesothelin and CA125\/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients","volume":"9","author":"Einama","year":"2021","journal-title":"Biomark. Res."},{"key":"10.1016\/j.cca.2025.120686_bb0755","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.3390\/diagnostics12122985","article-title":"The potential role of MUC16 (CA125) biomarker in lung Cancer: a magic biomarker but with adversity","volume":"12","author":"Saad","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.cca.2025.120686_bb0765","article-title":"Utility of BAP1 immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of malignant mesothelioma in effusion cytology specimens","volume":"40","author":"Hwang","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.cca.2025.120686_bb0770","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3892\/mco.2022.2594","article-title":"Expression of MUC1 in different tumours and its clinical significance (review)","volume":"17","author":"Lan","year":"2022","journal-title":"Molecular and Clinical Oncol."},{"key":"10.1016\/j.cca.2025.120686_bb0775","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3892\/ol.2021.12675","article-title":"Different role of MSLN and CA125 co-expression as a prognostic predictor between perihilar and distal bile duct carcinoma","volume":"21","author":"Takihata","year":"2021","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.cca.2025.120686_bb0780","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/srep01870","article-title":"Mesothelin binding to CA125\/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation","volume":"3","author":"Chen","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cca.2025.120686_bb0785","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1097\/MPA.0b013e318221bed8","article-title":"Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma","volume":"40","author":"Einama","year":"2011","journal-title":"Pancreas"},{"key":"10.1016\/j.cca.2025.120686_bb0790","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4240\/wjgs.v13.i5.406","article-title":"Benign vs malignant pancreatic lesions: molecular insights to an ongoing debate","volume":"13","author":"Aldyab","year":"2021","journal-title":"World J. Gastrointestinal Surgery"},{"key":"10.1016\/j.cca.2025.120686_bb0795","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.pan.2021.01.006","article-title":"Biomarkers of Chronic Pancreatitis: a systematic literature review","volume":"21","author":"Cruz-Monserrate","year":"2021","journal-title":"Pancreatology\u202f: Official J. Int. Association of Pancreatology (IAP) [et al]"},{"key":"10.1016\/j.cca.2025.120686_bb0800","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s10637-025-01517-8","article-title":"Retrospective analysis of clinical features of nivolumab-induced immune-related pancreatitis","volume":"43","author":"Pan","year":"2025","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.cca.2025.120686_bb0805","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/0192623309356449","article-title":"Useful immunohistochemical markers of tumor differentiation","volume":"38","author":"Painter","year":"2010","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.cca.2025.120686_bb0810","doi-asserted-by":"crossref","first-page":"27067","DOI":"10.18632\/oncotarget.8166","article-title":"Stability of the hybrid epithelial\/mesenchymal phenotype","volume":"7","author":"Jolly","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.cca.2025.120686_bb0815","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jare.2024.01.014","article-title":"The power and the promise of CAR-mediated cell immunotherapy for clinical application in pancreatic cancer","volume":"67","author":"Tang","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.cca.2025.120686_bb0820","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1053\/j.gastro.2022.03.056","article-title":"Pancreatic Cancer: pathogenesis, screening, diagnosis, and treatment","volume":"163","author":"Wood","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cca.2025.120686_bb0825","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.05.014","article-title":"Let\u2019s talk about sex: differences in drug therapy in males and females","volume":"175","author":"Madla","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.cca.2025.120686_bb0830","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101440","article-title":"Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment","volume":"21","author":"Zhang","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.cca.2025.120686_bb0835","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4103\/japtr.japtr_106_22","article-title":"Cancer and disease diagnosis - biosensor as potential diagnostic tool for biomarker detection","volume":"13","author":"Chaudhry","year":"2022","journal-title":"J. Adv. Pharm. Technol. Res."},{"key":"10.1016\/j.cca.2025.120686_bb0840","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.cdp.2006.03.004","article-title":"Real-time detection of mesothelin in pancreatic cancer cell line supernatant using an acoustic wave immunosensor","volume":"30","author":"Corso","year":"2006","journal-title":"Cancer Detect. Prev."},{"key":"10.1016\/j.cca.2025.120686_bb0845","article-title":"Multi-modality approaches for medical support systems: a systematic review of the last decade","volume":"103","author":"Salvi","year":"2024","journal-title":"Info. Fusion"},{"key":"10.1016\/j.cca.2025.120686_bb0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102435","article-title":"Advances in the use of Radiomics and Pathomics for predicting the efficacy of neoadjuvant therapy in tumors","volume":"58","author":"Wang","year":"2025","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.cca.2025.120686_bb0855","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1198\/sbr.2009.0002","article-title":"Methods for assessing improvement in specificity when a biomarker is combined with a standard screening test","volume":"1","author":"Shaw","year":"2009","journal-title":"Statistics in Biopharmaceutical Res."},{"key":"10.1016\/j.cca.2025.120686_bb0860","doi-asserted-by":"crossref","first-page":"422","DOI":"10.7150\/ijms.39012","article-title":"Overexpression of Mesothelin in pancreatic ductal adenocarcinoma (PDAC)","volume":"17","author":"Le","year":"2020","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.cca.2025.120686_bb0865","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3748\/wjg.v22.i3.1017","article-title":"How to predict clinical relapse in inflammatory bowel disease patients","volume":"22","author":"Liverani","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.cca.2025.120686_bb0870","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.cca.2025.120686_bb0875","doi-asserted-by":"crossref","DOI":"10.1016\/j.adcanc.2023.100098","article-title":"High expression of mesothelin in plasma and tissue is associated with poor prognosis and promotes invasion and metastasis in gastric cancer","volume":"7","author":"Saha","year":"2023","journal-title":"Adv. Cancer Biology - Metastasis."},{"key":"10.1016\/j.cca.2025.120686_bb0880","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of Mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial","volume":"155","author":"Beatty","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cca.2025.120686_bb0890","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3390\/vaccines13030314","article-title":"Anti-tumor efficacy of a Mesothelin-based Nanovaccine in a KPC Orthotopic mouse model of pancreatic Cancer","volume":"13","author":"Ferrari","year":"2025","journal-title":"Vaccines"},{"key":"10.1016\/j.cca.2025.120686_bb0915","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111481","article-title":"Rat N-ERC\/mesothelin as a marker for in vivo screening of drugs against pancreas cancer","volume":"9","author":"Fukamachi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2025.120686_bb0885","first-page":"12","article-title":"Cancer vaccine therapeutics: limitations and effectiveness-A literature review","author":"Kaczmarek","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.cca.2025.120686_bb0895","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/CCO.0000000000000006","article-title":"Current status of interleukin-10 and regulatory T-cells in cancer","volume":"25","author":"Dennis","year":"2013","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.cca.2025.120686_bb0900","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.coi.2008.04.008","article-title":"Regulatory T cells and treatment of cancer","volume":"20","author":"Curiel","year":"2008","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.cca.2025.120686_bb0905","article-title":"Stimulatory role of interleukin 10 in CD8(+) T cells through STATs in gastric cancer","volume":"39","author":"Xi","year":"2017","journal-title":"Tumour biology\u202f: J. Int. Soc. Oncodevelopmental Biology and Med."},{"key":"10.1016\/j.cca.2025.120686_bb0910","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1405267","article-title":"Emerging biomarkers for non-invasive diagnosis and treatment of cancer: a systematic review","volume":"14","author":"Zakari","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cca.2025.120686_bb0920","first-page":"192","article-title":"Anti-Mesothelin recombinant immunotoxin therapy for colorectal Cancer","volume":"18","author":"Cerise","year":"2019","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.cca.2025.120686_bb0925","first-page":"3520","article-title":"Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro","volume":"8","author":"Hassan","year":"2002","journal-title":"Clinical Cancer Res.: An Official J. American Association for Cancer Res."},{"key":"10.1016\/j.cca.2025.120686_bb0930","first-page":"1327","article-title":"Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas","volume":"24","author":"Li","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cca.2025.120686_bb0935","doi-asserted-by":"crossref","first-page":"7166","DOI":"10.1158\/1078-0432.CCR-07-1592","article-title":"Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts","volume":"13","author":"Hassan","year":"2007","journal-title":"Clinical Cancer Res.: An Official J. American Association for Cancer Res."},{"key":"10.1016\/j.cca.2025.120686_bb0940","doi-asserted-by":"crossref","first-page":"5926","DOI":"10.1158\/1078-0432.CCR-11-1235","article-title":"Killing of resistant cancer cells with low Bak by a combination of an antimesothelin immunotoxin and a TRAIL receptor 2 agonist antibody","volume":"17","author":"Du","year":"2011","journal-title":"Clinical Cancer Res.: An Official J. American Association for Cancer Res."},{"key":"10.1016\/j.cca.2025.120686_bb0945","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075576","article-title":"Combination treatments with the PKC inhibitor, enzastaurin, enhance the cytotoxicity of the anti-mesothelin immunotoxin, SS1P","volume":"8","author":"Mattoo","year":"2013","journal-title":"PloS One"},{"issue":"37","key":"10.1016\/j.cca.2025.120686_bb0950","first-page":"8","article-title":"Combining the antimesothelin immunotoxin SS1P with the BH3-mimetic ABT-737 induces cell death in SS1P-resistant pancreatic cancer cells","volume":"2014","author":"Hollevoet","year":"1997","journal-title":"J. Immunother."},{"key":"10.1016\/j.cca.2025.120686_bb0955","first-page":"5144","volume":"13","author":"Hassan","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.cca.2025.120686_bb0960","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1158\/1078-0432.CCR-09-0062","article-title":"Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P","volume":"15","author":"Kreitman","year":"2009","journal-title":"Clinical Cancer Res.: An Official J. American Association for Cancer Res."},{"key":"10.1016\/j.cca.2025.120686_bb0965","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1158\/0008-5472.CAN-14-0337","article-title":"Discovery of mesothelin and exploiting it as a target for immunotherapy","volume":"74","author":"Pastan","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.cca.2025.120686_bb0970","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin immunotherapy for Cancer: ready for prime time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cca.2025.120686_bb0975","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.molonc.2016.07.003","article-title":"Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy","volume":"10","author":"Bauss","year":"2016","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.cca.2025.120686_bb0980","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1158\/1535-7163.MCT-14-0132","article-title":"Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers","volume":"13","author":"Alewine","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.cca.2025.120686_bb0985","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122462","article-title":"Methylation-associated partial down-regulation of mesothelin causes resistance to anti-mesothelin immunotoxins in a pancreatic cancer cell line","volume":"10","author":"Hollevoet","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2025.120686_bb0990","doi-asserted-by":"crossref","first-page":"10666","DOI":"10.1073\/pnas.1611481113","article-title":"Actinomycin D enhances killing of cancer cells by immunotoxin RG7787 through activation of the extrinsic pathway of apoptosis","volume":"113","author":"Liu","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cca.2025.120686_bb0995","doi-asserted-by":"crossref","first-page":"87307","DOI":"10.18632\/oncotarget.20263","article-title":"Panbinostat decreases cFLIP and enhances killing of cancer cells by immunotoxin LMB-100 by stimulating the extrinsic apoptotic pathway","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cca.2025.120686_bb1000","doi-asserted-by":"crossref","first-page":"9189","DOI":"10.18632\/oncotarget.13984","article-title":"Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes","volume":"8","author":"Kolyvas","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cca.2025.120686_bb1005","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1158\/0008-5472.CAN-15-2401","article-title":"Anticancer effects of Mesothelin-targeted immunotoxin therapy are regulated by tyrosine kinase DDR1","volume":"76","author":"Ali-Rahmani","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.cca.2025.120686_bb1010","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1158\/1078-0432.CCR-19-2586","article-title":"Phase I\/II study of the Mesothelin-targeted immunotoxin LMB-100 with nab-paclitaxel for patients with advanced pancreatic adenocarcinoma","volume":"26","author":"Alewine","year":"2020","journal-title":"Clinical Cancer Res.: An Official J. American Association for Cancer Res."},{"key":"10.1016\/j.cca.2025.120686_bb1015","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1158\/2326-6066.CIR-16-0330","article-title":"Combining local immunotoxins targeting Mesothelin with CTLA-4 blockade synergistically eradicates murine Cancer by promoting anticancer immunity","volume":"5","author":"Leshem","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.cca.2025.120686_bb1020","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","article-title":"Mesothelin-targeted CARs: driving T cells to solid tumors","volume":"6","author":"Morello","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cca.2025.120686_bb1025","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","article-title":"Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers","volume":"16","author":"Hassan","year":"2010","journal-title":"Clinical Cancer Res.\u202f: An Official J. American Association for Cancer Res."},{"key":"10.1016\/j.cca.2025.120686_bb1030","first-page":"17","article-title":"Gemcitabine in advanced stage soft tissue sarcoma: a phase II study","volume":"150","author":"Amodio","year":"1999","journal-title":"Clin. Ter."},{"key":"10.1016\/j.cca.2025.120686_bb1035","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.18632\/oncotarget.2883","article-title":"Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging","volume":"6","author":"Lindenberg","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.cca.2025.120686_bb1040","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/B978-0-12-407190-2.00007-1","article-title":"Therapeutic cancer vaccines: past, present, and future","volume":"119","author":"Guo","year":"2013","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.cca.2025.120686_bb1045","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrclinonc.2014.111","article-title":"Therapeutic vaccines for cancer: an overview of clinical trials","volume":"11","author":"Melero","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cca.2025.120686_bb1050","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/sj.gt.3302974","article-title":"Control of human mesothelin-expressing tumors by DNA vaccines","volume":"14","author":"Chang","year":"2007","journal-title":"Gene Ther."},{"key":"10.1016\/j.cca.2025.120686_bb1055","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1752-8062.2008.00070.x","article-title":"Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma","volume":"1","author":"Leao","year":"2008","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.cca.2025.120686_bb1060","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.2001.19.1.145","article-title":"Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation","volume":"19","author":"Jaffee","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cca.2025.120686_bb1065","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/SLA.0b013e3181fd271c","article-title":"A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A phase II trial of safety, efficacy, and immune activation","volume":"253","author":"Lutz","year":"2011","journal-title":"Ann. Surg."},{"issue":"36","key":"10.1016\/j.cca.2025.120686_bb1070","first-page":"382","article-title":"Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer","volume":"2013","author":"Le","year":"1997","journal-title":"J. Immunother."},{"key":"10.1016\/j.cca.2025.120686_bb1075","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11605-012-2064-6","article-title":"Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study","volume":"17","author":"Hardacre","year":"2013","journal-title":"J. Gastrointestinal Surgery\u202f: Official J. Soc. Surgery of the Alimentary Tract."},{"key":"10.1016\/j.cca.2025.120686_bb1080","doi-asserted-by":"crossref","first-page":"13832","DOI":"10.1073\/pnas.0406035101","article-title":"Listeria-based cancer vaccines that segregate immunogenicity from toxicity","volume":"101","author":"Brockstedt","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cca.2025.120686_bb1085","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/1078-0432.CCR-11-2121","article-title":"A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction","volume":"18","author":"Le","year":"2012","journal-title":"Clinical Cancer Res.\u202f: An Official J. American Association for Cancer Res."},{"key":"10.1016\/j.cca.2025.120686_bb1090","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1177\/1756283X16667909","article-title":"Immunotherapy in pancreatic cancer treatment: a new frontier","volume":"10","author":"Thind","year":"2017","journal-title":"Therap. Adv. Gastroenterol."},{"key":"10.1016\/j.cca.2025.120686_bb1095","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1158\/1078-0432.CCR-07-0371","article-title":"Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation","volume":"14","author":"Laheru","year":"2008","journal-title":"Clinical Cancer Res.\u202f: An Official J. American Association for Cancer Res."},{"key":"10.1016\/j.cca.2025.120686_bb1100","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1200\/JCO.2014.57.4244","article-title":"Safety and survival with GVAX pancreas prime and Listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer","volume":"33","author":"Le","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cca.2025.120686_bb1105","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.1158\/1078-0432.CCR-18-2992","article-title":"Results from a phase IIb, randomized, multicenter study of GVAX pancreas and CRS-207 compared with chemotherapy in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE study)","volume":"25","author":"Le","year":"2019","journal-title":"Clinical Cancer Res.: an Official J. American Association for Cancer Res."},{"key":"10.1016\/j.cca.2025.120686_bb1110","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1053\/j.gastro.2012.12.042","article-title":"Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma","volume":"144","author":"Zheng","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cca.2025.120686_bb1115","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2326-6066.CIR-14-0027","article-title":"Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation","volume":"2","author":"Lutz","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"38","key":"10.1016\/j.cca.2025.120686_bb1120","first-page":"1","article-title":"PD-1\/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors","author":"Soares","year":"2015","journal-title":"J. Immunother.(Hagerstown, Md\u202f: 1997)"},{"key":"10.1016\/j.cca.2025.120686_bb1125","doi-asserted-by":"crossref","DOI":"10.5041\/RMMJ.10179","article-title":"Adoptive T cell immunotherapy for cancer","volume":"6","author":"Perica","year":"2015","journal-title":"Rambam Maimonides Med. J."},{"key":"10.1016\/j.cca.2025.120686_bb1130","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/cr.2016.154","article-title":"Driving gene-engineered T cell immunotherapy of cancer","volume":"27","author":"Johnson","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.cca.2025.120686_bb1135","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cca.2025.120686_bb1140","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cca.2025.120686_bb1145","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00262-025-04039-7","article-title":"Enhancing mesothelin CAR T cell therapy for pancreatic cancer with an oncolytic herpes virus boosting CAR target antigen expression","volume":"74","author":"Aboalela","year":"2025","journal-title":"Cancer Immunology, Immunotherapy\u202f: CII."},{"key":"10.1016\/j.cca.2025.120686_bb1150","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41392-024-01851-y","article-title":"Cancer stem cells: advances in knowledge and implications for cancer therapy","volume":"9","author":"Chu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cca.2025.120686_bb1155","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.neo.2021.12.005","article-title":"Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models","volume":"24","author":"Lee","year":"2022","journal-title":"Neoplasia (New York, NY)."},{"key":"10.1016\/j.cca.2025.120686_bb1160","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41572-021-00327-5","article-title":"Large-vessel vasculitis","volume":"7","author":"Pugh","year":"2022","journal-title":"Nat. Rev. DISEASE Primers"},{"key":"10.1016\/j.cca.2025.120686_bb1195","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006941","article-title":"Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression","volume":"5","author":"Hassan","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cca.2025.120686_bb1200","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.2147\/OTT.S145105","article-title":"Amatuximab and novel agents targeting mesothelin for solid tumors","volume":"10","author":"Baldo","year":"2017","journal-title":"Onco Targets Ther"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898125005650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898125005650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T17:28:17Z","timestamp":1766510897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898125005650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":239,"alternative-id":["S0009898125005650"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2025.120686","relation":{},"ISSN":["0009-8981"],"issn-type":[{"type":"print","value":"0009-8981"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mesothelin in pancreatic cancer: clinical applications and analytical considerations","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2025.120686","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120686"}}